✦ LIBER ✦

Oral and intravenously administered mTOR inhibitors for metastatic renal cell carcinoma: Pharmacokinetic considerations and clinical implications

✍ Scribed by Danesi, Romano; Boni, Joseph P.; Ravaud, Alain

Book ID: 121256728
Publisher: Elsevier Science
Year: 2013
Tongue: English
Weight: 547 KB
Volume: 39
Category: Article
ISSN: 0305-7372
DOI: 10.1016/j.ctrv.2012.12.012

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Pneumonitis associated with mTOR inhibit

Pneumonitis associated with mTOR inhibitors therapy in patients with metastatic renal cell carcinoma: Incidence, radiographic findings and correlation with clinical outcome

✍ Donnette A. Dabydeen; Jyothi P. Jagannathan; Nikhil Ramaiya; Katherine Krajewski 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 407 KB

PCN51 HEALTH CARE COSTS ASSOCIATED WITH

PCN51 HEALTH CARE COSTS ASSOCIATED WITH ANGIOGENESIS INHIBITORS (AIS) AND MTOR INHIBITORS (MTORS) IN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA (MRCC) TREATED AT US COMMUNITY ONCOLOGY CLINICS

✍ K Chen; SP Sarda; L Antràs; S Whittemore; A Luka; P Ramamurthy; J Scott; B Fortn 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 81 KB

Stage migration and increasing proportio

Stage migration and increasing proportion of favorable-prognosis metastatic renal cell carcinoma patients : Implications for clinical trial design and interpretation

✍ Sujata Patil; Nicole Ishill; John Deluca; Robert J. Motzer 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 195 KB

## Abstract ## BACKGROUND: The Memorial Sloan‐Kettering Cancer Center risk model classifies patients with metastatic renal cell carcinoma (RCC) by 5 pretreatment features as favorable, intermediate, and poor risk. The number of Memorial Sloan‐Kettering Cancer Center patients in each risk group was

Tyrosine Kinase Inhibitors Compared with

Tyrosine Kinase Inhibitors Compared with Cytokine Therapy for Metastatic Renal Cell Carcinoma: Overview of Recent Clinical Trials Differentiating Clinical Response and Adverse Effects

✍ Robert Dreicer 📂 Article 📅 2006 🏛 CIG Media Group, LP. 🌐 English ⚖ 151 KB

Angiogenesis inhibitor therapies for met

Angiogenesis inhibitor therapies for metastatic renal cell carcinoma: effectiveness, safety and treatment patterns in clinical practice-based on medical chart review

✍ Toni K. Choueiri; Mei Sheng Duh; Jessica Clement; Ashley J. Brick; Miranda J. Ro 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 270 KB 👁 1 views

PCN52 HEALTH CARE COSTS ASSOCIATED WITH

PCN52 HEALTH CARE COSTS ASSOCIATED WITH MULTIKINASE INHIBITORS (MKIS) FOR TREATMENT OF METASTATIC RENAL CELL CARCINOMA (MRCC) IN A CLINICAL PRACTICE SETTING IN ITALY

✍ C Paglino; C Porta; C Canipari; L Antràs; K Chen; S Whittemore; A Luka; P Ramamu 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 81 KB